We are live on ! Find out more
GNMK

GenMark Diagnostics, Inc
GNMK

Delisted

GNMK was delisted on the 21st of April, 2021.

Back to rankings

106 hedge funds and large institutions have $339M invested in GenMark Diagnostics, Inc in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 45 increasing their positions, 21 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 21

14% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 14

0% more funds holding

Funds holding: 106 → 106 (0)

8% less capital invested

Capital invested by funds: $368M → $339M (-$29.4M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $49K

Holders
106
Holders Change
–
Holders Change %
0%
% of All Funds
2.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
45
Reduced
21
Closed
14
Calls
–
Puts
$49K
Net Calls
-$49K
Net Calls Change
+$25K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$10.4M
2
CCM
Cadian Capital Management
New York
+$3.44M
3
N
Nuveen
North Carolina
+$2.93M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.46M
5
BlackRock
BlackRock
New York
+$1.36M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$7.76M
2
JP Morgan Chase
JP Morgan Chase
New York
-$7.31M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$2.81M
4
SSA
Schonfeld Strategic Advisors
New York
-$1.19M
5
Russell Investments Group
Russell Investments Group
United Kingdom
-$963K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
101
Tower Research Capital (TRC)
New York
$3K +$3.14K +446 New
CAC
102
Certified Advisory Corp
Florida
$2K – – –
Royal Bank of Canada
103
Royal Bank of Canada
Ontario, Canada
$2K +$2.63K +373 +9,325%
PHK
104
Point72 Hong Kong
Hong Kong
$1K +$782 +111 New
RE
105
RBC Europe
United Kingdom
$357 -$12.2K -1,735 -97%
GT
106
Glenmede Trust
Pennsylvania
$6 – – –
SSA
107
Schonfeld Strategic Advisors
New York
– -$1.19M -167,400 Closed
ARTA
108
A.R.T. Advisors
New York
– -$460K -64,911 Closed
DCM
109
Donaldson Capital Management
Indiana
– -$447K -63,003 Closed
Ameriprise
110
Ameriprise
Minnesota
– -$369K -51,986 Closed
BCM
111
Bridgeway Capital Management
Texas
– -$354K -49,900 Closed
SIM
112
Spark Investment Management
New York
– -$215K -30,418 Closed
Invesco
113
Invesco
Georgia
– -$185K -26,094 Closed
CCIA
114
Campbell & Co Investment Adviser
Maryland
– -$181K -25,481 Closed
JG
115
Jefferies Group
New York
– -$154K -21,652 Closed
DTL
116
Dynamic Technology Lab
Singapore
– -$133K -18,703 Closed
ECM
117
Element Capital Management
New York
– -$130K -18,353 Closed
JT
118
Jump Trading
Illinois
– -$122K -17,200 Closed
PP
119
Paloma Partners
Connecticut
– -$80K -11,262 Closed
AIC
120
Ameritas Investment Company
Nebraska
– -$43K -6,020 Closed
1 2 3 4
5

GNMK Hedge Fund Activity: Q2 2019 in Review

106 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q2 2019, worth a combined $339M — down 8% from $368M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new GNMK positions and 14 closed out — a net gain of 2 holders — while 45 added to existing stakes and 21 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $10.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $7.76M.

  • 106 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $339M of GenMark Diagnostics, Inc stock for Q2 2019, down 8% quarter-over-quarter.
  • 16 funds opened new GenMark Diagnostics, Inc positions in Q2 2019 and 14 closed out, a net change of +2 holders.
  • The largest GenMark Diagnostics, Inc buyer in Q2 2019 was Morgan Stanley, an estimated $10.4M added.
  • The largest GenMark Diagnostics, Inc seller in Q2 2019 was T. Rowe Price Associates, an estimated $7.76M sold.

Based on aggregated 13F filings for Q2 2019.